Successfully results from clinical study with Vacc-4x and Endocine
Oslo 10.05.2012 – Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x together with Endocine This New Option May Offer Easier Treatment Access for HIV Patients Globally News Summary * Vaccine related immune responses found in HIV patients given Vacc-4x together with Endocine through nasal administration in a placebo controlled …
HIV treatment with nasal-drop form
Oslo 10.04.2012 – Bionor Pharma ASA (OSE: BIONOR) today announces that the placebo controlled study of nasally administered HIV therapeutic vaccine Vacc-4x in combination with Eurocine Vaccines` Endocine has been finalized in Q1 as planned and previously communicated. 24 patients were included, and 23 completed the study. No serious adverse events have been reported. Analysis …
Vacc-4x phase IIB
Oslo 15.02.2012 – With final review of phase IIb viral load data completed, researchers confirm statistically significant reduction of HIV viral load on Vacc-4x compared to placebo. Bionor Pharma announced today that researchers have completed a final review of the Company`s lead therapeutic HIV vaccine, Vacc-4x, and its ability to reduce the amount of HIV …
Vacc-4x presented at AIDS Vaccine 2011 in Bangkok
(BANGKOK, Sep 12, 2011) Bionor Pharma presented Vacc-4x on “Global HIV Vaccine Enterprise” press conference at AIDS Vaccine 2011 in Bangkok. Results from Phase IIB Placebo Controlled Study of Bionor’s Vacc-4x show excellent safety profile and statistically significant viral load reduction in patients with HIV who suspend antiretroviral therapy. The vaccine, developed by Bionor Pharma, …
Clinical status for Vacc-4x and Revlimid®
BioCentury Publications, Inc., a leading provider of value-added information on strategic issues in life science, has in their report BioCentury Week in Review Aug 29, 2011, published the clinical status of the upcoming clinical trial regarding Bionor’s therapeutic vaccine, Vacc-4x in combination with Revlimid®. Link to the reprint
New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)
Oslo – 25.08.11 – Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug The study will determine: The target patient population for the study will be HIV-patients whose immune system have not fully recovered (defined by CD4+ (helper) T-cell count in the interval 250-400 cells …
BIOtechNOW: International AIDS Conference Unveils Four New “Next Generation” Treatments for HIV
New data presented at the 2010 International AIDS Conference showed significant momentum for the emerging fields of therapeutic vaccines, anti-immune hyperactivation, and other immune based therapies for the treatment of HIV/AIDS. New data presented by researchers at the XVIII International AIDS Conference on Thursday, July 22 showed significant momentum for the emerging field of therapeutic vaccines, anti-immune …
Successful therapeutic vaccination with Vacc-4x
Successful therapeutic vaccination of HIV patients with Vacc-4x, Bionor Pharma’s peptide-based therapeutic vaccine for HIV-1 infection Bionor Pharma announced today presentation of data from its international multicenter double-blinded placebo-controlled phase IIB study at the IAS conference in Rome. As previously communicated, a statistically significant difference in viral load set point was observed between the Vacc-4x …
Vacc-4x shows statistically significant reduction viral load
Further analysis of Vacc-4x phase IIb study shows a statistically significant reduction in viral load over placebo – Bionor Pharma reverses decision to put Vacc-4x on hold.